List view / Grid view
In this Q&A, Erik Wiklund, CEO of Circio, explains the key findings of their circVec circular RNA platform technology, why they chose AAV-based gene therapy for AATD as the lead programme, and their plans for the future to enhance the potency and reduce the cost of current gold-standard gene therapy.
In assays and patient-derived organoids, the small molecule inhibitor CBR-5884 successfully treated epithelial ovarian cancer.
The experimental therapy eliminated 90 percent of HSV-1 after facial infection and 97 percent of HSV-1 after genital infection.
Through in vitro and in vivo models, researchers find a mechanism by which bacteria-generated fatty acids regulate immune responses.
In animal studies, the new vaccine construct outperformed another PNAG-vaccine delivery system currently in human trials.
The pharmacological inhibition of class IIa HDACs could be a therapeutic approach for addressing Th17-related inflammatory and autoimmune diseases.
The new findings could result in a clinical trial to assess whether a one-year course of treatment could stop brain tumours.
In this Q&A, Curve Therapeutic’s Chief Scientific Officer Professor Ali Tavassoli discusses how dual HIF inhibition could combat solid tumours.
Dr Fernández-Capetillo shares his insights from a recent study conducted at the CNIO, elucidating how the expression of (PR)arginine-rich peptides affects ribosomal protein translation and accumulation, and how accelerated aging can be alleviated.
The compound 11c demonstrates an excellent safety profile and is an exciting advancement in liver disease management.
Stem-cell based blastocyst models have enabled scientists to redefine the molecular signature and timing of the onset of gastrulation.
In this Q&A, Aki Ko, CEO and co-founder of Elixirgen Therapeutics, elucidates how their new mRNA technology could potentially restore muscle function in those suffering from Duchenne muscular dystrophy.
Results from an in vivo CRISPR knockout screen, targeting genes involved in autophagy, could lead to new therapies.
We had the privilege of speaking to Dr Víctor Sebastián Pérez, Associate Director of Computational Drug Design, following his presentation at ELRIG UK 2023. He shares his insights into how Exscientia is using AI to design drug candidates for cancer treatment.
Researchers have uncovered the role of the PL-BLA neuronal axis and its potential function in DOP-mediated anxiolytic effects.
